Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm Receives $4.5M R&D Tax Incentive

Monday, July 21, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has secured a $4.5 million research and development tax incentive, which will bolster its ongoing clinical studies. This funding is expected to enhance the company's innovative efforts in the biopharma sector. The tax incentive underscores the potential of Radiopharm's projects and their significance in advancing therapeutic options.
Price reaction · baseline $4.41 (2025-07-21T14:54:00.000Z) · hit during market hours · 2 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm received a substantial $4.5 million R&D tax incentive.
  • This funding supports ongoing clinical studies and research initiatives.
  • The incentive reflects confidence in Radiopharm's innovative approaches.

Full Press Release Details

• Announcements , Updates
• PDF
• July 21, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• November 22, 2022
• Announcements
• June 30, 2023
• Announcements
• November 29, 2022
• Announcements
• September 20, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the amount of the R&D tax incentive Radiopharm received?

Radiopharm received a $4.5 million research and development tax incentive.

How will the tax incentive benefit Radiopharm?

The tax incentive will support ongoing clinical studies and research initiatives.

What does this funding reflect about Radiopharm?

The funding reflects confidence in Radiopharm's innovative approaches in biopharma.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm R&D tax incentive clinical studies biopharma theranostics
Last updated: Jul 21, 2025